INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in Light Delivery Device (LDD) sales, light adjustable intraocular lenses utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following the announcement, RxSight's stock price fell by $4.84 per share, or 37.84%, closing at $7.95 per share on July 9, 2025 [3]. Legal Context - Investors who purchased or acquired RxSight securities during the Class Period have until September 22, 2025, to request appointment as Lead Plaintiff [2]. - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation [4].